Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
354 hedge funds and large institutions have $8.24B invested in Blueprint Medicines in 2025 Q2 according to their latest regulatory filings, with 110 funds opening new positions, 94 increasing their positions, 118 reducing their positions, and 106 closing their positions.
222% more funds holding in top 10
Funds holding in top 10: 9 → 29 (+20)
35% more capital invested
Capital invested by funds: $6.12B → $8.24B (+$2.13B)
4% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 106
1% more funds holding
Funds holding: 352 → 354 (+2)
8.57% less ownership
Funds ownership: 108.16% → 99.58% (-8.6%)
20% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 118
32% less call options, than puts
Call options by funds: $144M | Put options by funds: $210M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$405M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$203M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$183M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$176M |
| 5 |
Barclays
London,
United Kingdom
|
+$148M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$410M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$361M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$274M |
| 4 |
JP Morgan Chase
New York
|
-$217M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$148M |
BPMC Hedge Fund Activity: Q2 2025 in Review
354 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2025, worth a combined $8.24B — up 35% from $6.12B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new BPMC positions and 106 closed out — a net gain of 4 holders — while 94 added to existing stakes and 118 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $405M. The largest seller was T. Rowe Price Associates, cutting an estimated $410M.
- 354 institutional investors held Blueprint Medicines (BPMC) as of Q2 2025, up from 352 in Q1 2025.
- Funds reported $8.24B of Blueprint Medicines stock for Q2 2025, up 35% quarter-over-quarter.
- 110 funds opened new Blueprint Medicines positions in Q2 2025 and 106 closed out, a net change of +4 holders.
- The largest Blueprint Medicines buyer in Q2 2025 was Pentwater Capital Management, an estimated $405M added.
- The largest Blueprint Medicines seller in Q2 2025 was T. Rowe Price Associates, an estimated $410M sold.
Based on aggregated 13F filings for Q2 2025.